Prime Medicine utilizes Prime Editing, a precise gene editing technology that enables the targeted replacement of faulty DNA sequences without causing double-strand breaks. This approach aims to directly correct genetic mutations responsible for debilitating diseases, potentially offering long-lasting therapeutic benefits.
Funding
$55M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BMFounders
Product
Problem
Many genetic diseases are caused by specific DNA mutations. Traditional gene editing techniques often introduce unintended double-strand breaks, leading to potential off-target effects and safety concerns.
Solution
Prime Medicine is developing Prime Editing, a gene editing technology designed to precisely correct faulty DNA sequences at their specific location in the genome without creating double-strand breaks. This "search and replace" approach aims to directly address the genetic root cause of diseases by replacing the disease-causing sequence with the correct DNA sequence. The technology is designed to be versatile and efficient across a wide range of gene mutations, organisms, organs, and cell types. By minimizing unwanted DNA modifications, Prime Editing seeks to offer long-lasting therapeutic benefits with improved safety profiles compared to traditional methods.
Target Audience
The primary target audience includes patients suffering from debilitating genetic diseases and the medical community seeking safer and more effective gene editing therapies.
Features
- Precise, targeted correction of genetic mutations without double-strand DNA breakage
- Versatile application across various organisms, organs, and cell types
- Designed to minimize off-target effects and unwanted DNA modifications
- Potential to address approximately 90% of known disease-causing mutations